Compare Cytokinetics Inc (CYTK) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Boston Beer Company Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Boston Beer Company Inc trades at $170.51 (market cap $1.76B). The key difference: Cytokinetics Inc is far larger — about 4.9× Boston Beer Company Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Boston Beer Company Inc for 59 Days on average.
| CYTK | SAM | |
|---|---|---|
Market Cap | $8.62B | $1.76B |
Volume | 2,594,626 | 264,496 |
Sector | Health | Consumer Staples |
52-Week High | $87.26 | $260.05 |
52-Week Low | $54.76 | $161.08 |
Typical Hold Time | 19 Days | 59 Days |
Enterprise Value | $8.72B | $1.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.91, up 2.93% with bearish technical signals despite strong analyst support. The company shows promising drug development with positive Phase 3 results for aficamten in HCM treatment, though fundamentals remain challenged with a P/S ratio of 114 and negative profit margins. Recent executive stock sales and high cash burn from operations highlight ongoing financial pressures despite growing revenue potential from new drug launches.
The outlook balances significant upside potential from analyst price targets averaging $112.60 against substantial execution risks. While clinical successes position CYTK for growth in cardiovascular treatments, persistent losses and high valuation metrics require careful risk assessment. The stock offers speculative growth opportunity but demands close monitoring of commercialization progress and path to profitability.
Boston Beer Company (SAM) trades at $170.51, up 1.4% with a bullish technical signal despite recent earnings misses. The stock shows mixed fundamentals with a P/E of 22.66 and negative net margin of -3.64%, though operating cash flow remains strong at $270M. Recent news highlights brand innovation including new cocktail products and marketing partnerships, while analyst consensus leans heavily toward Hold (71.87%) with a $204.44 price target.
SAM faces headwinds from declining alcohol consumption and cost pressures, but brand investments and new product launches offer growth potential. The stock trades near support at $169 with upside to analyst targets, though execution risks and margin pressure require monitoring. Current valuation appears reasonable relative to historical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
